Evidence map›Paper›PMID 42492735›Full record

ReviewVirus research2026

The PTM switches of HBx: Master regulators of HBV infection and liver oncogenesis.

Zubing Ye, Meijuan Ma, Di Yu, Yibo Hu, Yan Liu, Jun Zhao, Zhanhai Su, Xiaohui Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zubing YeDepartment of Pathogen Biology and Immunology, School of Medicine, Qinghai University, Qinghai, China.
Meijuan MaDepartment of Pathogen Biology and Immunology, School of Medicine, Qinghai University, Qinghai, China.
Di YuDepartment of Pathogen Biology and Immunology, School of Medicine, Qinghai University, Qinghai, China.
Yibo HuDepartment of Orthopaedic Trauma, The Affiliated Hospital of Qinghai University, Qinghai, China.
Yan LiuDepartment of Pathogen Biology and Immunology, School of Medicine, Qinghai University, Qinghai, China; Highland Cardio-Cerebrovascular Health Engineering Medicine Joint Research Center, Qinghai University, China.
Jun ZhaoDepartment of Pathogen Biology and Immunology, School of Medicine, Qinghai University, Qinghai, China.
Zhanhai SuHighland Cardio-Cerebrovascular Health Engineering Medicine Joint Research Center, Qinghai University, China; Qinghai Institute of Technology, China. Electronic address: suzhanhai@qhu.edu.cn.
Xiaohui ZhaoDepartment of Pathogen Biology and Immunology, School of Medicine, Qinghai University, Qinghai, China; Highland Cardio-Cerebrovascular Health Engineering Medicine Joint Research Center, Qinghai University, China. Electronic address: 2022990093@qhu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The hepatitis B virus (HBV) X protein (HBx) functions as a versatile regulatory molecule that is indispensable for both efficient HBV replication and the pathogenesis of HBV-related hepatocellular carcinoma (HCC). Accumulating studies indicate that a broad spectrum of post-translational modifications (PTMs), including ubiquitination, phosphorylation, NEDDylation and ISGylation, critically influence HBx stability, intracellular trafficking, and its capacity to engage with diverse host factors. Collectively, these PTMs constitute a complex modulatory network that governs viral persistence and contributes to malignant transformation in the liver. In this review, we synthesize recent advances in deciphering the molecular principles that drive HBx PTMs and delineate their functional consequences during HBV infection and HCC development. We also summarize current understanding of how HBV manipulates host PTM systems to optimize its life cycle while promoting oncogenic processes. Furthermore, the review discusses emerging therapeutic opportunities centered on modulating HBx PTMs, with the aim of informing the design of next-generation antiviral and anti-tumor interventions.

Indexed as

CarcinogenesisCarcinoma, HepatocellularHepatitis BHepatitis B virusLiver NeoplasmsProtein Processing, Post-TranslationalTrans-ActivatorsViral Regulatory and Accessory ProteinsAnimalsHost-Pathogen InteractionsHumansVirus Replicationhepatitis B virus X proteinTrans-ActivatorsViral Regulatory and Accessory ProteinsHBx proteinHepatitis B virusHepatocellular carcinomaPost-translational modificationsViral infection

Identifiers

PMID42492735
PMCPMC13486377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.